Recommendations from the Investigational New Drug/Investigational Device Exemption Task Force of the Clinical and Translational Science Award consortium: Developing and implementing a sponsor-investigators training program

M. E Blair Holbein, Jelena Petrovic Berglund, Erin K. O'Reilly, Karen Hartman, Lisa A. Speicher, Joan E. Adamo, Gerri O'Riordan, Jennifer Swanton Brown, Kathryn G. Schuff

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: The objective of this study was to provide recommendations for provision of training for sponsor and investigators at Academic Health Centers. Background: A subgroup of the Investigational New Drug/Investigational Device Exemption (IND/IDE) Task Force of the Clinical and Translational Science Award (CTSA) program Regulatory Knowledge Key Function Committee was assembled to specifically address how clinical investigators who hold an IND/IDE and thus assume the role of sponsorinvestigators are adequately trained to meet the additional regulatory requirements of this role. Methods: The participants who developed the recommendations were representatives of institutions with IND/IDE support programs. Through an informal survey, the task force determined that a variety and mix of models are used to provide support for IND/IDE holders within CTSA institutions. In addition, a CTSA consortium-wide resources survey was used. The participants worked from the models and survey results to develop consensus recommendations to address institutional support, training content, and implementation. Recommendations: The CTSA IND/IDE Task Force recommendations are as follows: (1) Institutions should assess the scope of Food and Drug AdministrationYregulated research, perform a needs analysis, and provide resources to implement a suitable training program; (2) The model of training program should be tailored to each institution; (3) The training should specifically address the unique role of sponsor-investigators, and the effectiveness of training should be evaluated regularly by methods that fit the model adopted by the institution; and (4) Institutional leadership should mandate sponsor-investigator training and effectively communicate the necessity and availability of training.

Original languageEnglish (US)
Pages (from-to)797-803
Number of pages7
JournalJournal of Investigative Medicine
Volume62
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Investigational Drugs
Advisory Committees
Research Personnel
Education
Equipment and Supplies
Training Support
Consensus
Health
Availability
Food
Research
Pharmaceutical Preparations
Surveys and Questionnaires

Keywords

  • Academic Health Center
  • Clinical and Translational Science Award
  • FDA-regulated research
  • Investigational Device Exemption
  • Investigational New Drug
  • Regulatory knowledge
  • Sponsor-investigator

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Recommendations from the Investigational New Drug/Investigational Device Exemption Task Force of the Clinical and Translational Science Award consortium : Developing and implementing a sponsor-investigators training program. / Holbein, M. E Blair; Berglund, Jelena Petrovic; O'Reilly, Erin K.; Hartman, Karen; Speicher, Lisa A.; Adamo, Joan E.; O'Riordan, Gerri; Brown, Jennifer Swanton; Schuff, Kathryn G.

In: Journal of Investigative Medicine, Vol. 62, No. 5, 2014, p. 797-803.

Research output: Contribution to journalArticle

Holbein, M. E Blair ; Berglund, Jelena Petrovic ; O'Reilly, Erin K. ; Hartman, Karen ; Speicher, Lisa A. ; Adamo, Joan E. ; O'Riordan, Gerri ; Brown, Jennifer Swanton ; Schuff, Kathryn G. / Recommendations from the Investigational New Drug/Investigational Device Exemption Task Force of the Clinical and Translational Science Award consortium : Developing and implementing a sponsor-investigators training program. In: Journal of Investigative Medicine. 2014 ; Vol. 62, No. 5. pp. 797-803.
@article{74cc247cf7b14da18f8058f811472bbe,
title = "Recommendations from the Investigational New Drug/Investigational Device Exemption Task Force of the Clinical and Translational Science Award consortium: Developing and implementing a sponsor-investigators training program",
abstract = "Objective: The objective of this study was to provide recommendations for provision of training for sponsor and investigators at Academic Health Centers. Background: A subgroup of the Investigational New Drug/Investigational Device Exemption (IND/IDE) Task Force of the Clinical and Translational Science Award (CTSA) program Regulatory Knowledge Key Function Committee was assembled to specifically address how clinical investigators who hold an IND/IDE and thus assume the role of sponsorinvestigators are adequately trained to meet the additional regulatory requirements of this role. Methods: The participants who developed the recommendations were representatives of institutions with IND/IDE support programs. Through an informal survey, the task force determined that a variety and mix of models are used to provide support for IND/IDE holders within CTSA institutions. In addition, a CTSA consortium-wide resources survey was used. The participants worked from the models and survey results to develop consensus recommendations to address institutional support, training content, and implementation. Recommendations: The CTSA IND/IDE Task Force recommendations are as follows: (1) Institutions should assess the scope of Food and Drug AdministrationYregulated research, perform a needs analysis, and provide resources to implement a suitable training program; (2) The model of training program should be tailored to each institution; (3) The training should specifically address the unique role of sponsor-investigators, and the effectiveness of training should be evaluated regularly by methods that fit the model adopted by the institution; and (4) Institutional leadership should mandate sponsor-investigator training and effectively communicate the necessity and availability of training.",
keywords = "Academic Health Center, Clinical and Translational Science Award, FDA-regulated research, Investigational Device Exemption, Investigational New Drug, Regulatory knowledge, Sponsor-investigator",
author = "Holbein, {M. E Blair} and Berglund, {Jelena Petrovic} and O'Reilly, {Erin K.} and Karen Hartman and Speicher, {Lisa A.} and Adamo, {Joan E.} and Gerri O'Riordan and Brown, {Jennifer Swanton} and Schuff, {Kathryn G.}",
year = "2014",
doi = "10.231/JIM.0000000000000083",
language = "English (US)",
volume = "62",
pages = "797--803",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Recommendations from the Investigational New Drug/Investigational Device Exemption Task Force of the Clinical and Translational Science Award consortium

T2 - Developing and implementing a sponsor-investigators training program

AU - Holbein, M. E Blair

AU - Berglund, Jelena Petrovic

AU - O'Reilly, Erin K.

AU - Hartman, Karen

AU - Speicher, Lisa A.

AU - Adamo, Joan E.

AU - O'Riordan, Gerri

AU - Brown, Jennifer Swanton

AU - Schuff, Kathryn G.

PY - 2014

Y1 - 2014

N2 - Objective: The objective of this study was to provide recommendations for provision of training for sponsor and investigators at Academic Health Centers. Background: A subgroup of the Investigational New Drug/Investigational Device Exemption (IND/IDE) Task Force of the Clinical and Translational Science Award (CTSA) program Regulatory Knowledge Key Function Committee was assembled to specifically address how clinical investigators who hold an IND/IDE and thus assume the role of sponsorinvestigators are adequately trained to meet the additional regulatory requirements of this role. Methods: The participants who developed the recommendations were representatives of institutions with IND/IDE support programs. Through an informal survey, the task force determined that a variety and mix of models are used to provide support for IND/IDE holders within CTSA institutions. In addition, a CTSA consortium-wide resources survey was used. The participants worked from the models and survey results to develop consensus recommendations to address institutional support, training content, and implementation. Recommendations: The CTSA IND/IDE Task Force recommendations are as follows: (1) Institutions should assess the scope of Food and Drug AdministrationYregulated research, perform a needs analysis, and provide resources to implement a suitable training program; (2) The model of training program should be tailored to each institution; (3) The training should specifically address the unique role of sponsor-investigators, and the effectiveness of training should be evaluated regularly by methods that fit the model adopted by the institution; and (4) Institutional leadership should mandate sponsor-investigator training and effectively communicate the necessity and availability of training.

AB - Objective: The objective of this study was to provide recommendations for provision of training for sponsor and investigators at Academic Health Centers. Background: A subgroup of the Investigational New Drug/Investigational Device Exemption (IND/IDE) Task Force of the Clinical and Translational Science Award (CTSA) program Regulatory Knowledge Key Function Committee was assembled to specifically address how clinical investigators who hold an IND/IDE and thus assume the role of sponsorinvestigators are adequately trained to meet the additional regulatory requirements of this role. Methods: The participants who developed the recommendations were representatives of institutions with IND/IDE support programs. Through an informal survey, the task force determined that a variety and mix of models are used to provide support for IND/IDE holders within CTSA institutions. In addition, a CTSA consortium-wide resources survey was used. The participants worked from the models and survey results to develop consensus recommendations to address institutional support, training content, and implementation. Recommendations: The CTSA IND/IDE Task Force recommendations are as follows: (1) Institutions should assess the scope of Food and Drug AdministrationYregulated research, perform a needs analysis, and provide resources to implement a suitable training program; (2) The model of training program should be tailored to each institution; (3) The training should specifically address the unique role of sponsor-investigators, and the effectiveness of training should be evaluated regularly by methods that fit the model adopted by the institution; and (4) Institutional leadership should mandate sponsor-investigator training and effectively communicate the necessity and availability of training.

KW - Academic Health Center

KW - Clinical and Translational Science Award

KW - FDA-regulated research

KW - Investigational Device Exemption

KW - Investigational New Drug

KW - Regulatory knowledge

KW - Sponsor-investigator

UR - http://www.scopus.com/inward/record.url?scp=84902182221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902182221&partnerID=8YFLogxK

U2 - 10.231/JIM.0000000000000083

DO - 10.231/JIM.0000000000000083

M3 - Article

C2 - 24831858

AN - SCOPUS:84902182221

VL - 62

SP - 797

EP - 803

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 5

ER -